Meryn Grant represents corporations and their executives in securities class actions, litigation relating to mergers and acquisitions, and complex commercial litigation.

Ms. Grant helps clients navigate the full lifecycle of high-stakes litigation. She regularly represents market-leading companies in matters involving:

  • Securities class actions
  • Shareholder derivative litigation
  • Mergers and acquisitions litigation
  • Internal investigations
  • Complex, high-exposure litigation

She guides clients through high-publicity matters and develops a unified strategy that aggressively advances a company’s position while protecting its reputation.

Ms. Grant’s trial experience includes a rare Rule 10b-5 class action and serving as lead attorney in a four-day federal jury trial.

As she previously served as an internal auditor to a public company, Ms. Grant intimately understands public company accounting and financial statements. Combining her academic background in statistics and knowledge of Food and Drug Administration regulatory approvals, she offers clients strategic insight in their most business-critical situations.

Ms. Grant’s active pro bono practice involves matters relating to criminal justice and sentencing reform.

Before joining the firm, Ms. Grant served as a law clerk to Alaska Supreme Court Justice Walter L. Carpeneti. While attending Stanford Law School, she was an article editor for the Stanford Journal of Law, Business & Finance.

Ms. Grant’s experience includes representing:

Initial Public Offering Litigation

  • A data storage company and its officers and directors in state and federal securities class actions relating to one of 2017’s largest IPOs, securing a stay in state court and a partial dismissal in federal court
  • YogaWorks and its officers and directors in a federal securities class action alleging material misstatements and omissions in IPO offering materials, in which the court granted Latham’s motion to dismiss all claims with prejudice, resulting in the dismissal of a parallel class action in state court

Biopharmaceutical Litigation

  • Allergan, a global pharmaceutical company, in litigation arising from Valeant Pharmaceuticals International and Pershing Square’s US$53 billion hostile takeover attempt, in which the court found that the lawsuit raised “serious questions” about the defendants’ potential violations of the insider trading laws
  • ChemoCentryx, a biopharmaceutical company, in a securities class action filed in the Northern District of California alleging violations of Section 10(b) and 20(a) of the Securities Exchange Act
  • Puma Biotechnology in a securities class action trial involving its Phase III clinical trial results, defeating more than 95% of the plaintiffs’ claimed damages in a rare Section 10(b) securities class action to go to jury verdict, which the Daily Journal named as one of the Top Verdicts of 2019
  • Zogenix in a federal securities class action alleging material misstatements and omissions regarding its new drug application submission disclosures, in which the court granted Latham’s motion to dismiss

High-Exposure Litigation

  • CoreCivic Inc. (formerly Corrections Corporation of America), a private prison operator before the US District Court for the Middle District of Tennessee regarding allegations that CoreCivic misrepresented its safety, security and rehabilitation standards; the matter settled
  • A Swiss-based multinational oilfield service and technology company in securities fraud class actions and derivative actions related to the restatement of its financial statements due to tax accounting errors
  • US Soccer Federation in a high-profile summary judgment victory as lead trial counsel in litigation with the US Senior Women’s National Team regarding equal pay

M&A Litigation

  • Excel Trust in several lawsuits challenging its US$2 billion merger with The Blackstone Group, obtaining dismissal of a San Diego Superior Court action and denial of class action plaintiffs’ motion for preliminary injunction
  • Receptos in shareholder litigation related to its US$7.2 billion sale to Celgene Corporation

Bar Qualification

  • California

Education

  • JD, Stanford Law School, 2012
  • BA, Colorado College, 2008

Languages Spoken

  • English